71.71
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NFLX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$73.17
Offen:
$71.965
24-Stunden-Volumen:
34.81M
Relative Volume:
0.83
Marktkapitalisierung:
$298.60B
Einnahmen:
$48.77B
Nettoeinkommen (Verlust:
$13.65B
KGV:
22.59
EPS:
3.1742
Netto-Cashflow:
$11.15B
1W Leistung:
+2.31%
1M Leistung:
+0.43%
6M Leistung:
-14.11%
1J Leistung:
-38.15%
Netflix Inc Stock (NFLX) Company Profile
Firmenname
Netflix Inc
Sektor
Branche
Telefon
408-540-3700
Adresse
121 ALBRIGHT WAY, LOS GATOS
Compare NFLX vs DIS, WBD, LYV, FWONK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
NFLX
Netflix Inc
|
71.71 | 293.14B | 48.77B | 13.65B | 11.15B | 3.1742 |
|
DIS
Walt Disney Co
|
96.20 | 167.83B | 97.37B | 12.34B | 7.11B | 6.2499 |
|
WBD
Warner Bros Discovery Inc
|
26.30 | 63.38B | 37.25B | -1.71B | 2.31B | -0.6988 |
|
LYV
Live Nation Entertainment Inc
|
174.19 | 41.75B | 25.61B | -229.57M | 1.21B | -1.7628 |
|
FWONK
Liberty Media Corp
|
98.13 | 24.64B | 4.75B | 822.00M | 730.00M | 3.1136 |
Netflix Inc Stock (NFLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Herabstufung | Erste Group | Buy → Hold |
| 2026-04-20 | Bestätigt | Bernstein | Outperform |
| 2026-04-06 | Hochstufung | Goldman | Neutral → Buy |
| 2026-03-30 | Eingeleitet | Citizens | Mkt Perform |
| 2026-03-24 | Hochstufung | Erste Group | Hold → Buy |
| 2026-03-18 | Fortgesetzt | Citigroup | Buy |
| 2026-03-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2026-03-02 | Fortgesetzt | Barclays | Equal Weight |
| 2026-03-02 | Fortgesetzt | JP Morgan | Overweight |
| 2026-02-27 | Hochstufung | Arete | Neutral → Buy |
| 2026-02-27 | Fortgesetzt | Evercore ISI | Outperform |
| 2026-01-23 | Bestätigt | Robert W. Baird | Outperform |
| 2026-01-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2026-01-21 | Bestätigt | Canaccord Genuity | Buy |
| 2026-01-21 | Bestätigt | Deutsche Bank | Hold |
| 2026-01-21 | Bestätigt | Goldman | Neutral |
| 2026-01-21 | Bestätigt | Guggenheim | Buy |
| 2026-01-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2026-01-21 | Bestätigt | Morgan Stanley | Overweight |
| 2026-01-21 | Bestätigt | Needham | Buy |
| 2026-01-21 | Bestätigt | Oppenheimer | Outperform |
| 2026-01-21 | Bestätigt | Piper Sandler | Overweight |
| 2026-01-21 | Bestätigt | Pivotal Research Group | Hold |
| 2026-01-21 | Bestätigt | Rosenblatt | Neutral |
| 2026-01-21 | Bestätigt | Rothschild & Co Redburn | Buy |
| 2026-01-21 | Bestätigt | TD Cowen | Buy |
| 2026-01-21 | Bestätigt | UBS | Buy |
| 2026-01-21 | Bestätigt | Wolfe Research | Outperform |
| 2026-01-12 | Eingeleitet | HSBC Securities | Buy |
| 2026-01-09 | Bestätigt | Goldman | Neutral |
| 2025-12-08 | Herabstufung | Pivotal Research Group | Buy → Hold |
| 2025-12-08 | Herabstufung | Rosenblatt | Buy → Neutral |
| 2025-11-18 | Bestätigt | Barclays | Equal Weight |
| 2025-10-31 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-07 | Hochstufung | Seaport Research Partners | Neutral → Buy |
| 2025-09-17 | Hochstufung | Loop Capital | Hold → Buy |
| 2025-07-10 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2025-07-07 | Herabstufung | Seaport Research Partners | Buy → Neutral |
| 2025-07-02 | Bestätigt | Canaccord Genuity | Buy |
| 2025-07-02 | Bestätigt | Goldman | Neutral |
| 2025-06-20 | Bestätigt | Pivotal Research Group | Buy |
| 2025-06-12 | Bestätigt | Oppenheimer | Outperform |
| 2025-06-03 | Bestätigt | Jefferies | Buy |
| 2025-05-30 | Bestätigt | BofA Securities | Buy |
| 2025-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-04-21 | Bestätigt | Barclays | Equal Weight |
| 2025-04-21 | Bestätigt | Canaccord Genuity | Buy |
| 2025-04-21 | Bestätigt | Guggenheim | Buy |
| 2025-04-21 | Bestätigt | JP Morgan | Overweight |
| 2025-04-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2025-04-21 | Bestätigt | MoffettNathanson | Buy |
| 2025-04-21 | Bestätigt | Morgan Stanley | Overweight |
| 2025-04-21 | Bestätigt | Oppenheimer | Outperform |
| 2025-04-21 | Bestätigt | Piper Sandler | Overweight |
| 2025-04-21 | Bestätigt | Pivotal Research Group | Buy |
| 2025-04-21 | Bestätigt | Wells Fargo | Overweight |
| 2025-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-27 | Eingeleitet | FBN Securities | Outperform |
| 2025-03-17 | Hochstufung | MoffettNathanson | Neutral → Buy |
| 2025-01-24 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-01-23 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-01-22 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-01-22 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2025-01-22 | Bestätigt | Pivotal Research Group | Buy |
| 2025-01-22 | Hochstufung | Rosenblatt | Neutral → Buy |
| 2025-01-22 | Hochstufung | The Benchmark Company | Sell → Hold |
| 2025-01-16 | Hochstufung | Seaport Research Partners | Neutral → Buy |
| 2025-01-15 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-01-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-01-08 | Bestätigt | Goldman | Neutral |
| 2025-01-06 | Bestätigt | Argus | Buy |
| 2025-01-03 | Bestätigt | The Benchmark Company | Sell |
| 2024-12-19 | Bestätigt | UBS | Buy |
| 2024-12-16 | Herabstufung | Loop Capital | Buy → Hold |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-11 | Bestätigt | JP Morgan | Overweight |
| 2024-11-20 | Bestätigt | Pivotal Research Group | Buy |
| 2024-10-18 | Bestätigt | Needham | Buy |
| 2024-10-18 | Bestätigt | Oppenheimer | Outperform |
| 2024-10-18 | Bestätigt | Pivotal Research Group | Buy |
| 2024-10-16 | Bestätigt | Loop Capital | Buy |
| 2024-10-11 | Bestätigt | Guggenheim | Buy |
| 2024-10-10 | Bestätigt | Morgan Stanley | Overweight |
| 2024-10-10 | Bestätigt | Oppenheimer | Outperform |
| 2024-10-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-10-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-10-01 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-09-05 | Eingeleitet | China Renaissance | Hold |
| 2024-08-30 | Bestätigt | Pivotal Research Group | Buy |
| 2024-07-17 | Bestätigt | Guggenheim | Buy |
| 2024-07-16 | Bestätigt | The Benchmark Company | Sell |
| 2024-07-15 | Bestätigt | BofA Securities | Buy |
| 2024-07-12 | Bestätigt | JP Morgan | Overweight |
| 2024-07-10 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-07-09 | Bestätigt | TD Cowen | Buy |
| 2024-07-02 | Bestätigt | Argus | Buy |
| 2024-05-28 | Bestätigt | Evercore ISI | Outperform |
| 2024-04-19 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-04-19 | Hochstufung | Needham | Hold → Buy |
| 2024-04-19 | Bestätigt | Pivotal Research Group | Buy |
| 2024-04-15 | Bestätigt | Deutsche Bank | Hold |
| 2024-04-12 | Bestätigt | Morgan Stanley | Overweight |
| 2024-04-12 | Bestätigt | Piper Sandler | Neutral |
| 2024-04-05 | Bestätigt | Pivotal Research Group | Buy |
| 2024-03-25 | Bestätigt | Citigroup | Neutral |
| 2024-03-12 | Bestätigt | Jefferies | Buy |
| 2024-03-11 | Bestätigt | Oppenheimer | Outperform |
| 2024-01-30 | Herabstufung | Seaport Research Partners | Buy → Neutral |
| 2024-01-25 | Hochstufung | DZ Bank | Hold → Buy |
| 2024-01-24 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-01-24 | Bestätigt | BofA Securities | Buy |
| 2024-01-24 | Bestätigt | Canaccord Genuity | Buy |
| 2024-01-24 | Bestätigt | Evercore ISI | Outperform |
| 2024-01-24 | Bestätigt | Goldman | Neutral |
| 2024-01-24 | Bestätigt | Guggenheim | Buy |
| 2024-01-24 | Bestätigt | JP Morgan | Overweight |
| 2024-01-24 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-01-24 | Hochstufung | Macquarie | Neutral → Outperform |
| 2024-01-24 | Bestätigt | Morgan Stanley | Overweight |
| 2024-01-24 | Bestätigt | Oppenheimer | Outperform |
| 2024-01-24 | Bestätigt | Piper Sandler | Neutral |
| 2024-01-24 | Bestätigt | Pivotal Research Group | Buy |
| 2024-01-24 | Bestätigt | Redburn Atlantic | Buy |
| 2024-01-24 | Bestätigt | Robert W. Baird | Outperform |
| 2024-01-24 | Bestätigt | TD Cowen | Outperform |
| 2024-01-24 | Bestätigt | UBS | Buy |
| 2024-01-24 | Bestätigt | Wells Fargo | Overweight |
| 2023-09-18 | Bestätigt | Evercore ISI | Outperform |
| 2023-08-25 | Hochstufung | Loop Capital | Hold → Buy |
| 2023-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-07-17 | Bestätigt | Deutsche Bank | Buy |
| 2023-07-13 | Bestätigt | JP Morgan | Overweight |
| 2023-07-12 | Bestätigt | UBS | Buy |
| 2023-07-05 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-29 | Bestätigt | Citigroup | Buy |
| 2023-06-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-06-13 | Bestätigt | BofA Securities | Buy |
| 2023-06-13 | Bestätigt | Guggenheim | Buy |
| 2023-04-19 | Bestätigt | Deutsche Bank | Buy |
| 2023-04-19 | Bestätigt | JP Morgan | Overweight |
| 2023-04-19 | Bestätigt | Jefferies | Buy |
| 2023-04-19 | Bestätigt | Piper Sandler | Neutral |
| 2023-04-19 | Bestätigt | Pivotal Research Group | Buy |
| 2023-04-19 | Bestätigt | Rosenblatt | Neutral |
| 2023-04-19 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-11 | Fortgesetzt | Robert W. Baird | Neutral |
| 2023-01-23 | Bestätigt | Argus | Buy |
| 2023-01-20 | Bestätigt | Canaccord Genuity | Buy |
| 2023-01-20 | Bestätigt | Deutsche Bank | Buy |
| 2023-01-20 | Bestätigt | Evercore ISI | Outperform |
| 2023-01-20 | Bestätigt | Goldman | Sell |
| 2023-01-20 | Bestätigt | Guggenheim | Buy |
| 2023-01-20 | Bestätigt | Jefferies | Buy |
| 2023-01-20 | Bestätigt | MoffettNathanson | Market Perform |
| 2023-01-20 | Bestätigt | Oppenheimer | Outperform |
| 2023-01-20 | Bestätigt | Piper Sandler | Neutral |
| 2023-01-20 | Bestätigt | Pivotal Research Group | Buy |
| 2023-01-20 | Bestätigt | Robert W. Baird | Neutral |
| 2023-01-20 | Bestätigt | The Benchmark Company | Sell |
| 2023-01-20 | Bestätigt | Wedbush | Outperform |
| 2023-01-20 | Bestätigt | Wolfe Research | Outperform |
| 2023-01-12 | Hochstufung | Jefferies | Hold → Buy |
| 2023-01-04 | Eingeleitet | New Street | Neutral |
| 2022-12-29 | Hochstufung | CFRA | Sell → Buy |
| 2022-12-14 | Bestätigt | Jefferies | Hold |
| 2022-12-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-06-14 | Herabstufung | The Benchmark Company | Hold → Sell |
| 2022-06-10 | Herabstufung | Goldman | Neutral → Sell |
| 2022-05-16 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-04-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-04-21 | Herabstufung | Edward Jones | Buy → Hold |
| 2022-04-20 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-04-20 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-04-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-04-20 | Hochstufung | Needham | Underperform → Hold |
| 2022-04-20 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-04-20 | Herabstufung | Pivotal Research Group | Buy → Sell |
| 2022-04-20 | Herabstufung | Stifel | Buy → Hold |
| 2022-04-20 | Herabstufung | UBS | Buy → Neutral |
| 2022-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-19 | Eingeleitet | Rosenblatt | Neutral |
| 2022-03-09 | Hochstufung | Wedbush | Underperform → Neutral |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Edward Jones | Hold → Buy |
| 2022-01-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-01-21 | Bestätigt | BofA Securities | Buy |
| 2022-01-21 | Bestätigt | Canaccord Genuity | Buy |
| 2022-01-21 | Bestätigt | Cowen | Outperform |
| 2022-01-21 | Bestätigt | Deutsche Bank | Hold |
| 2022-01-21 | Bestätigt | Goldman | Neutral |
| 2022-01-21 | Bestätigt | Guggenheim | Buy |
| 2022-01-21 | Bestätigt | JP Morgan | Overweight |
| 2022-01-21 | Bestätigt | MoffettNathanson | Neutral |
| 2022-01-21 | Herabstufung | Monness Crespi & Hardt | Buy → Neutral |
| 2022-01-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-21 | Bestätigt | Oppenheimer | Outperform |
| 2022-01-21 | Bestätigt | Piper Sandler | Overweight |
| 2022-01-21 | Bestätigt | Pivotal Research Group | Buy |
| 2022-01-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-01-21 | Bestätigt | Stifel | Buy |
| 2022-01-21 | Hochstufung | The Benchmark Company | Sell → Hold |
| 2022-01-21 | Herabstufung | Truist | Buy → Hold |
| 2022-01-21 | Bestätigt | UBS | Buy |
| 2022-01-21 | Bestätigt | Wolfe Research | Outperform |
| 2021-12-15 | Bestätigt | The Benchmark Company | Sell |
| 2021-10-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-10-20 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2021-09-29 | Bestätigt | The Benchmark Company | Sell |
| 2021-09-13 | Eingeleitet | Goldman | Neutral |
| 2021-09-08 | Bestätigt | JP Morgan | Overweight |
| 2021-09-07 | Bestätigt | Atlantic Equities | Overweight |
| 2021-07-21 | Bestätigt | Credit Suisse | Outperform |
| 2021-07-21 | Bestätigt | Deutsche Bank | Buy |
| 2021-07-21 | Bestätigt | JP Morgan | Overweight |
| 2021-07-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2021-07-21 | Bestätigt | Stifel | Buy |
| 2021-06-25 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-06-25 | Eingeleitet | Edward Jones | Hold |
| 2021-05-19 | Fortgesetzt | Jefferies | Buy |
| 2021-04-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2021-04-21 | Bestätigt | Pivotal Research Group | Buy |
| 2021-04-21 | Hochstufung | Stifel | Hold → Buy |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-04-01 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-25 | Bestätigt | The Benchmark Company | Sell |
| 2021-03-23 | Hochstufung | Argus | Hold → Buy |
| 2021-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-01-20 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2021-01-20 | Bestätigt | Pivotal Research Group | Buy |
| 2021-01-20 | Bestätigt | The Benchmark Company | Sell |
| 2021-01-20 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2020-10-21 | Bestätigt | Bernstein | Outperform |
| 2020-10-21 | Bestätigt | Jefferies | Buy |
| 2020-10-21 | Bestätigt | Morgan Stanley | Overweight |
| 2020-10-21 | Bestätigt | Oppenheimer | Outperform |
| 2020-10-21 | Bestätigt | Piper Sandler | Overweight |
| 2020-10-21 | Bestätigt | Pivotal Research Group | Buy |
| 2020-10-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-10-21 | Bestätigt | The Benchmark Company | Sell |
| 2020-10-21 | Bestätigt | Wedbush | Underperform |
| 2020-10-21 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-10-16 | Bestätigt | Morgan Stanley | Overweight |
| 2020-10-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-10-14 | Bestätigt | Goldman | Buy |
| 2020-10-07 | Bestätigt | Pivotal Research Group | Buy |
| 2020-09-28 | Bestätigt | The Benchmark Company | Sell |
| 2020-09-15 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-09 | Fortgesetzt | Raymond James | Mkt Perform |
| 2020-09-04 | Bestätigt | The Benchmark Company | Sell |
| 2020-07-29 | Bestätigt | Loop Capital | Buy |
Alle ansehen
Netflix Inc Aktie (NFLX) Neueste Nachrichten
‘Below’: Josh Harnett Protects His Town From A Mysterious Sea Creature In Trailer For Netflix Drama Series — Watch - Deadline
Netflix sets theatrical releases for Lee Chang-dong’s ‘Possible Love’ - IMDb
Netflix: Too Many Tailwinds For The Stock To Stay Down, Long-Term (NASDAQ:NFLX) - Seeking Alpha
Netflix Stock: Buy or Sell? My Final Verdict - The Motley Fool
Netflix is removing "magnificent" period drama with Florence Pugh and James Norton very soon - Yahoo
The Manufacturers Life Insurance Company Sells 68,074 Shares of Netflix, Inc. $NFLX - MarketBeat
Evelyn Partners Investment Management Services Ltd Acquires 17,319 Shares of Netflix, Inc. $NFLX - MarketBeat
Southpoint Capital Advisors LP Makes New Investment in Netflix, Inc. $NFLX - MarketBeat
Saba Capital Management L.P. Invests $3.12 Million in Netflix, Inc. $NFLX - MarketBeat
Lazard Asset Management LLC Grows Stock Holdings in Netflix, Inc. $NFLX - MarketBeat
Netflix: Time to Buy the Post-Earnings Dip? - The Motley Fool
Gateway Wealth Partners LLC Grows Stock Position in Netflix, Inc. $NFLX - MarketBeat
Netflix: The Market Still Isn't Pricing In The Ad Business - Seeking Alpha
Whoopi Goldberg Set for Netflix Comedy Movie ‘Women Like Us’ with Star-Studded Cast - IMDb
Lee Chang-dong’s Venice and Toronto-Bound ‘Possible Love’ Sets Theatrical Release Dates Ahead of Netflix Bow - Variety
Netflix, Inc. $NFLX Shares Sold by Elite Wealth Management Inc. - MarketBeat
Empowered Funds LLC Has $82.53 Million Holdings in Netflix, Inc. $NFLX - MarketBeat
Netflix (NFLX) Faces Kalshi Demand To Remove Prediction Games Trailer - simplywall.st
Arrowstreet Capital Limited Partnership Lowers Stock Position in Netflix, Inc. $NFLX - MarketBeat
Netflix Sets Launch Date for Lee Chang-dong’s Awards Hopeful ‘Possible Love’ - IMDb
Netflix has acquired non-exclusive international rights to Power, Ghost, Raising Kanan & Force, along with domestic rights to the mothership series. Read more below. - facebook.com
Writing Netflix Off Now Would Be A Mistake - Seeking Alpha
Bank of America (NYSE: BAC), Netflix (NASDAQ: NFLX) And TotalEnergies (NYSE: TTE) Lead Monday Analyst Stock Roundup - foreignpolicyjournal.com
Netflix Stock Investors Need to Understand This Huge Risk - The Motley Fool
Netflix Inc Lobbyists, 2024 - OpenSecrets
Netflix exec claims ketamine confession in ‘trust exercise’ cost him $1.1M job: lawsuit - Fox News
Exclusive | Millionaire Netflix exec exposes workplace culture after being fired for retreat ‘confession’: suit - New York Post
Netflix Is Quietly Abandoning the Strategy That Made It a Giant - Collider
What’s coming to Netflix in August 2026: movies, series, documentaries and specials - Diario AS
A Netflix Company Retreat Sparked a Lawsuit. Experts Say the Real Damage May Be Just Beginning - inc.com
Netflix dodges defamation suit over troubled teen documentary 'The Program' - Courthouse News
Kalshi Threatens Netflix With Defamation Suit Over Prediction Markets Documentary Trailer - Law Commentary
Netflix's 6-Part Action Series Is Officially One Of The Biggest Streaming Shows In The World - IMDb
Minka Kelly's Steamy Western Series Is Taking Over Netflix's Charts - IMDb
He Opened Up at a Netflix Retreat ‘Trust’ Exercise—Then, He Was Fired - inc.com
Netflix faces cease-and-desist over controversial scene in new documentary - Fast Company
Full List: All 89 Movies & Shows That Now Feature Sign Language Support on Netflix - What's on Netflix
Top Stock Reports for Bank of America, Netflix & TotalEnergies - Zacks Investment Research
‘The Truthers’ Netflix Review: Spanish Conspiracy Thriller Is a Chilling Character Study - What's on Netflix
TF1+ Reaches 44 Million Monthly Streamers: Netflix Carrier Deal Proves European Blueprint - Tech Times
Is Netflix Inc (NASDAQ:NFLX) Changing How Often It Shares Engagement Data? - Kalkine Media
Think You Can Beat Darts Superstar Luke Littler? Netflix Opens Entries for Live Sports Show - IMDb
Power Is Coming to Netflix - Netflix
Whoopi Goldberg, Jenifer Lewis, Vanessa Williams, Vivica A. Fox to Star in ‘Women Like Us for Netflix - The Hollywood Reporter
Production starts on ‘Myron Bolitar’ Netflix series - My Clallam County
The Gilded Age’s Morgan Spector to Play Robert Langdon in Netflix’s New Series Adapting Dan Brown’s ‘Secret of Secrets’ - IMDb
‘Women Like Us’: Whoopi Goldberg & All-Star Cast to Star in New Netflix Comedy Movie - What's on Netflix
‘The Cackling of the Dodos’: Jason Bateman Netflix Movie Wraps Filming with Sam Rockwell & Woody Harrelson - IMDb
Beat Luke Littler: UK Darts Event Gives Amateurs a Chance at Life-Changing Money - IMDb
Netflix stock trades near 2022 lows despite str... - Pluang
Netflix executive reveals at company's trust-building retreat he once used ketamine, got fired from his $ - The Times of India
Finanzdaten der Netflix Inc-Aktie (NFLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Netflix Inc-Aktie (NFLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SMITH BRADFORD L | Director |
Jun 17 '26 |
Option Exercise |
10.42 |
35,990 |
374,933 |
115,680 |
| SMITH BRADFORD L | Director |
Jun 17 '26 |
Sale |
77.52 |
35,990 |
2,789,799 |
79,690 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):